English
|
Spanish
Supporting oncology professionals through education
Login
Register
The content on this site is intended for healthcare professionals only
Menu
Home
News
Journal
Video
e
learning
Events
Conferences
About us
Keyword
Breast
Prostate & urology
Lung & pleura
Colorectal & gastro
Melanoma & skin
Head & neck
Ovary & gynaecology
Bone
Brain & nervous system
Haematology oncology
Hepatobiliary pancreatic
Paediatric
Neuroendocrine
Sarcomas
News
Latest news
Sign up for news alerts
Submit your news
Explore
Bone
Brain & nervous system
Breast
Colorectal & gastro
Haematology oncology
Head & neck
Hepatobiliary pancreatic
Lung & pleura
Melanoma & skin
Neuroendocrine
Ovary & gynaecology
Paediatric
Prostate & urology
Sarcomas
Journal information
Journal home
Charges
Editorial board
Founding editors
Editor-in-chief
Contact us
Author information
Submit article
Author guidelines
Editorial policies
Copyright information
Why publish with us
Reviewer information
Reviewer guidelines
Memberships
Videos
Recent videos
Sign up
Explore
Bone
Brain & nervous system
Breast
Colorectal & gastro
Haematology oncology
Head & neck
Hepatobiliary pancreatic
Lung & pleura
Melanoma & skin
Neuroendocrine
Ovary & gynaecology
Paediatric
Prostate & urology
Sarcomas
Conferences
Latest conferences
Sign up for latest coverage
Submit your event
About
e
cancer
About
e
cancer
Our founders
Funding statement
Contact us
Home
News
Journal
Video
e
learning
Events
Conferences
About us
Keyword
Breast
Prostate & urology
Lung & pleura
Colorectal & gastro
Melanoma & skin
Head & neck
Ovary & gynaecology
+
-
Bone
Brain & nervous system
Haematology oncology
Hepatobiliary pancreatic
Paediatric
Neuroendocrine
Sarcomas
Selecting appropriate first line lung cancer therapy
Share :
AACR 2009
18 - 22 Apr 2009
Please rate this video
The information in this video was of interest to me
The information in this video is likely to improve my clinical practice or research
I would recommend this video to my colleagues
Published:
8 Jul 2009
Views:
15794
Rating:
Save
Rate video
Dr Paul Bunn - University of Colorado, Denver, USA
erlotininb, cetuximab or gefitinib for lung cancer in pill form- less toxic and better tolerated, better survival for patients with EGFR gene mutation.
Categories:
Lung & pleura
Biology
Targeted molecules
Related Videos
ASCO 2024: Lung cancer highlights
Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas...
26 Jun 2024
ASCO 2024: Lung cancer roundup
Dr Luis Raez - Memorial Cancer Institute, Miami, USA
4 Jun 2024
ASCO 2024: Advances in NSCLC
Dr Enriqueta Felip, Dr Alex Spira, Dr Antonio Passaro and Dr Alfredo Addeo
3 Jun 2024
Osimertinib success in locally advanced EGFR-mutated NSCLC
Dr Suresh Ramalingam - Emory University School of Medicine, Atlanta, USA
3 Jun 2024
Ivonescimab benefit for EGFR mutant NSCLC patients who failed TKI therapy
Prof Li Zhang - Sun Yat-Sen University Cancer Center, Guangzhou, China
1 Jun 2024
Avelumab plus platinum-based chemotherapy may show some efficacy in patients...
Dr Giannis Mountzios - Henry Dunant Hospital Center, Athens, Greece
26 Apr 2024
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...
25 Mar 2024
Updates on lung cancer from WCLC and ESMO 2023
Dr Luis Raez - Memorial Cancer Institute, Miami, USA
31 Jan 2024
ESMO 2023: Highlights and analysis
Dr Bishal Gyawali - Queen's University, Kingston, Canada
8 Nov 2023
More from
e
cancer